Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886678 | 0.81 | TSHR (0.40) | GBA1TSHRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL31632607 | 0.79 | CYP2C19 (0.48) | GBA1NR3C1TSHRALDH1A1CYP2C19 | |
| SCHEMBL12930943 | 0.79 | TMEM97 (0.42) | GBA1NR3C1TSHRALDH1A1KDM4E | |
| SCHEMBL31623051 | 0.77 | CYP2C19 (0.40) | GBA1NR3C1TSHRALDH1A1KDM4E | |
| SCHEMBL1907350 | 0.75 | GBA1 (0.41) | GBA1NR3C1TSHRALDH1A1KDM4E | |
| SCHEMBL28496421 | 0.75 | CYP2C19 (0.52) | GBA1NR3C1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12982419 | 0.73 | CYP2C19 (0.50) | NR3C1TSHRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1859320 | 0.72 | CRHBP (0.54) | NR3C1TSHRSMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL11296484 | 0.72 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL11299583 | 0.71 | TSHR (0.38) | GBA1NR3C1TSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130131013-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-6716491-B2 | BASED ON MIXTURE OF POLAR COMPOUNDS OF POSITIVE DIELECTRIC ANISOTROPY; FOR USE IN MATRIX LIQUID CRYSTAL AND TWISTED/SUPERTWISTED NEMATIC CELLS | MERCK PATENT GMBH (DE) | 2004-04-06 | — | — | US | disclosed |
| US-20020030180-A1 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | GBA1 138/4885NR3C1 1479/4885KDM1A 263/4885 |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ALK, BRAF, BMX | GBA1 962/4885NR3C1 1974/4885KDM1A 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.